Open Access

REVIEW

MOHAMMAD AMIN ELAHI NAJAFI^1,2,#, TAKUO MATSUKAWA^1,2,#, HIROSHI MIYAMOTO^1,2,3,*
Oncology Research, Vol.33, No.6, pp. 1255-1270, 2025, DOI:10.32604/or.2025.062142 - 29 May 2025
Abstract Sex hormones, including androgens and estrogens, are known to have widespread physiological actions beyond the reproductive system via binding to their cognitive receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, a growing body of evidence has indicated the involvement of androgen receptor, as well as estrogen receptors such as estrogen receptor-α and estrogen receptor-β, in the pathogenesis and growth of various types of malignancies, including urothelial cancer. Additionally, in bladder cancer, the activity of sex hormone receptors has been implicated in modulating sensitivity to conventional non-surgical therapy. These may More >

View

564

Download

261

Open Access

REVIEW

HYEON JI KIM^1,#, BO KYUNG JOO^1,#, JIN-SEOK BYUN^2,3,*, DO-YEON KIM^1,3,*
Oncology Research, Vol.33, No.6, pp. 1271-1282, 2025, DOI:10.32604/or.2025.062207 - 29 May 2025
Abstract Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive and devastating disease arising primarily from the mucosal epithelium of the oral cavity, pharynx, and larynx. HNSCC ranks as the sixth most common cancer worldwide, carrying significant morbidity and mortality. HPV-positive HNSCC can be partially prevented with the FDA-approved HPV vaccine and generally exhibits a more favorable prognosis compared to HPV-negative cases. However, effective screening and treatment approaches remain elusive for HPV-negative HNSCC. While precancerous lesions may precede invasive cancer in certain situations, most patients present with advanced disease without prior indication of precancerous More >

View

505

Download

304

Open Access

REVIEW

GIOVANA GOMES CHAGAS¹, RUAN PIMENTA², NAYARA IZABEL VIANA^1,*
Oncology Research, Vol.33, No.6, pp. 1283-1288, 2025, DOI:10.32604/or.2025.055100 - 29 May 2025
Abstract The monoclonal antibodies consist of an innovative form of immunotherapy, capable of defeating several diseases, such as cancer. It is an emergent and important theme, that advances evaluation, challenges, and future perspectives with high relevance to identify gaps in recent studies and to consolidate this general theme in only one research. Its action in Chronic and Acute Lymphoid Leukemia has been evaluated in several clinical trials, which were selected between 2022 and 2023, in order to understand better the monoclonal antibodies that were most studied. The biopharmaceutical compounds Ibrutinib, Obinutuzumab, Rituximab, Venetoclax, and Inotuzumab Ozogamicin… More >

View

528

Download

267

Open Access

REVIEW

ABDUR JAMIL¹, RIMSHA SIDDIQUE², FARYAL ALTAF³, DANIYAL WARRAICH⁴, FAIZAN AHMED⁵, ZAHEER QURESHI^6,*
Oncology Research, Vol.33, No.6, pp. 1289-1300, 2025, DOI:10.32604/or.2025.058790 - 29 May 2025
Abstract Background: Male breast cancer (MBC) is a rare but significant health concern, accounting for less than 1% of all breast cancer cases. Despite its low incidence, it presents unique clinical, genetic, and psychosocial challenges. Genetic predispositions, including BRCA2 mutations and hormonal imbalances, are key factors influencing the development of MBC. However, the rarity of the condition has led to limited research and fewer treatment guidelines specifically for male patients. Methods: A comprehensive literature review was conducted using PubMed, MEDLINE, and Embase databases to identify studies focusing on the epidemiology, risk factors, clinical presentation, diagnosis, treatment,… More >

View

643

Download

325

Open Access

REVIEW

ASHUTOSH KUMAR MAURYA¹, ANJALI SANGEETH¹, RABINA PUNATHIL¹, R. GRACE RAJI¹, V.B. SAMEER KUMAR^2,*
Oncology Research, Vol.33, No.6, pp. 1301-1321, 2025, DOI:10.32604/or.2025.055945 - 29 May 2025
Abstract Carcinogenesis is a multilevel process characterized by genetic and epigenetic alterations, thus contributing to uncontrolled proliferation that eventually leads to cancer. The process of carcinogenesis involves an intricate dis-orchestration in the expression of both, coding and non-coding sequences and is also dependent on the reprogramming of energy metabolism as both direct and indirect consequence of oncogenic mutations. Dysregulated mitochondrial energetics is an important hallmark of cancer, where cancer cells switch to the glycolytic pathway as an alternate source of energy to support the continuous energy supply needed for their indefinite growth. Even though functional mitochondria… More >

View

636

Download

347

Open Access

REVIEW

JUNPING LIU^1,2, FEIRAN GAO¹, DANTING WANG², RUIXUE ZHOU², CHUNYAN HUANG^2,*
Oncology Research, Vol.33, No.6, pp. 1323-1334, 2025, DOI:10.32604/or.2024.059113 - 29 May 2025
Abstract Exosomes (EXOs) play an important role in the progression of breast cancer. EXOs, with a diameter of approximately 100 nm, have a simple structure but diverse functions, and can affect the development of breast cancer through signal transduction and molecular transfer, etc. Angiogenesis provides nutrients for the growth and metastasis of breast cancer and is a crucial part of tumor progression. The mechanism of tumor angiogenesis is complex. The VEGF/VEGFR pathway promotes angiogenesis by regulating the activities of ECs. Hypoxia, a common feature in the tumor microenvironment, as a key regulator, can affect angiogenesis… More >

Graphic Abstract

View

727

Download

337

Open Access

REVIEW

JIE ZHONG¹, JUE LIU¹, XING TANG², WENCHAO ZHOU², GUANGMING SONG¹, YUHUAN ZENG¹, XIAODI ZHANG¹, JIANBIN ZHOU¹, JieZhou¹, LU CAO¹, QUNFENG ZHANG^1,*, YUKUN LI^2,*
Oncology Research, Vol.33, No.6, pp. 1335-1346, 2025, DOI:10.32604/or.2025.058760 - 29 May 2025
Abstract The cell cycle is a tightly coupled series of events that enable cells to grow and proliferate. Cyclin-dependent kinases (CDKs) play crucial roles in the cell cycle by enabling cells to transition between different phases when they are activated. Cell cycle proteins enhance the activity of CDKs, while natural CDK inhibitors (CDKIs) suppress them. The cell cycle continues in cycles under normal conditions, but when conditions change, cells halt or terminate the cell cycle. Tumors are tissues that grow out of control, and the mechanisms of various types of tumors are different; however, almost… More >

Graphic Abstract

View

687

Download

269

Open Access

REVIEW

YU HONG^1,#, YUNXIANG TANG^1,#, WENYAN ZHOU¹, HANYUE LUO², LINLIN BU², HUI QIU^3,*, QIUJI WU^3,*
Oncology Research, Vol.33, No.6, pp. 1347-1361, 2025, DOI:10.32604/or.2025.059327 - 29 May 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract As a rising immune checkpoint on tumor cells, CD24 is closely related to tumorigenesis and progression. CD24 can directly regulate the malignant behavior of tumor cells and indirectly inhibit the function of immune cells in the meantime, which promotes the immune escape of tumor cells, induces cancer invasion and causes poor prognosis. The basic principle of cancer treatment is to induce cell death and inhibit cell survival. Resistance to chemoradiotherapy is a critical challenge in oncology, which limits the effectiveness of anti-cancer treatments. Many studies have shown a strong association between CD24 and chemoradiotherapy More >

View

749

Download

322

Open Access

REVIEW

YUZHENG LI^1,2, LILI YU¹, SHIYAO ZHOU¹, HUA ZHOU^2,3,*, QIBIAO WU^1,2,*
Oncology Research, Vol.33, No.6, pp. 1363-1376, 2025, DOI:10.32604/or.2025.059311 - 29 May 2025
（This article belongs to the Special Issue: Multi-Omics Approaches for Precision Medicine)
Abstract Background: Non-small cell lung cancer (NSCLC) involves complex alterations in the epidermal growth factor receptor (EGFR) signaling pathway. This study aims to integrate multimodal omics analyses to evaluate and enhance EGFR-targeted therapies. Methods: We reviewed and synthesized omics data—including genomics, transcriptomics, proteomics, epigenomics, and metabolomics data—related to the EGFR pathway in NSCLC, examined the clinical outcomes of current therapies and proposed new treatment strategies. Results: Integrated omics analyses revealed the multifaceted role of EGFR in NSCLC. Transcriptomic analysis revealed gene expression alterations due to EGFR mutations, with upregulation of oncogenes and downregulation of tumor suppressors. Proteomics More >

View

834

Download

402

Open Access

ARTICLE

THAINá RODRIGUES^1,2, PATRíCIA CANDIDO^1,3, FERES CAMARGO MALUF¹, POLIANA ROMãO¹, CAROLINA MIE MIOSHI¹, VANESSA RIBEIRO GUIMARãES¹, JULIANA ALVES DE CAMARGO¹, KARINA SERAFIM DA SILVA^1,4, GABRIEL ARANTES DOS SANTOS¹, IRAN AMORIM SILVA¹, KATIA RAMOS MOREIRA LEITE¹, WILLIAM C. NAHAS⁵, SABRINA T. REIS^1,3, RUAN PIMENTA^1,6, NAYARA IZABEL VIANA^1,7,*
Oncology Research, Vol.33, No.6, pp. 1377-1382, 2025, DOI:10.32604/or.2025.055306 - 29 May 2025
Abstract Objectives: Bladder Cancer (BC) is one of the most commonly diagnosed malignancies worldwide, with high rates of mortality and morbidity. It can be classified as non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC), with radical cystectomy being the treatment for MIBC, which significantly reduces quality of life. MicroRNAs (miRs) act as critical genetic regulators, with both oncogenic and tumor-suppressive roles. MiR-10a is described as a tumor suppressor in various neoplasms, but its role in BC is controversial. This study aims to assess the activity of miR-10a in cellular invasion and proliferation in two… More >

View

438

Download

237

Open Access

ARTICLE

Yinghui Ye^1,#, Yulou Luo^2,#, Yutian Sun³, Yujie Zhang¹, Jiaxin Lin⁴, Ziling Yang⁵, Anping Xu^6,*, Bei Xue^1,*
Oncology Research, Vol.33, No.6, pp. 1383-1404, 2025, DOI:10.32604/or.2025.062584 - 29 May 2025
Abstract Objectives: The tumorigenic progression of Lung adenocarcinoma (LUAD), the predominant NSCLC subtype, is predominantly driven by co-occurring mutations in KRAS proto-oncogene (KRAS)/Tumor protein p53 (TP53). However, their impact on tumor microenvironment (TME) heterogeneity, particularly neutrophil dynamics, remains poorly understood. This present study aims to elucidate how KRAS/TP53 mutations reprogram the TME and develop a neutrophil-centric prognostic signature for LUAD. Methods: Leveraging single-cell RNA sequencing data and transcriptome data, neutrophil subpopulations were identified using Seurat and CellChat R packages, with trajectory analysis via Monocle2 R package. High-dimensional weighted gene co-expression network analysis (hdWGCNA), univariate Cox regression,… More >

View

527

Download

424

Open Access

ARTICLE

LIBO LIANG¹, XINYI WANG^2,3,4, YUPING ZENG^2,3,4, HAO CHEN^2,3,4, WEN ZHOU¹, HONGYING MU^2,3,4, GA LIAO^5,6,*
Oncology Research, Vol.33, No.6, pp. 1405-1421, 2025, DOI:10.32604/or.2024.056708 - 29 May 2025
Abstract Objectives: Exosomal long noncoding RNAs (lncRNAs) might facilitate epithelial–mesenchymal transition (EMT) in liver cancer after transarterial chemoembolization (TACE), thereby enhancing tumor cell invasiveness and migration. This study investigated the prognostic role of plasma exosomal long noncoding RNA-plasmacytoma variant translocation 1 (lncRNA-PVT1) in TACE treated hepatocellular carcinoma (HCC). Methods: Plasma exosomal lncRNA-PVT1 was evaluated via qPCR before and after TACE. Hepatoma cell behavior was investigated in different HCC cell lines. A lncRNA-PVT1 plasmid was synthesized and overexpressed, and si-lncRNA PVT1 was transfected into poorly invasive cells to reveal its influence on cell characteristics. The lncRNA-PVT1–FoxM1 interaction… More >

Graphic Abstract

View

703

Download

374

Open Access

ARTICLE

JIANMIAO YANG^1,2,#, XIAOYAN SUN^3,#, TIANTIAN WANG¹, HAIQING ZHONG^1,3, MIN HAN^1,3, WUPING SHUAI^4,5,6,*, DONGHANG XU^1,*
Oncology Research, Vol.33, No.6, pp. 1423-1436, 2025, DOI:10.32604/or.2025.058997 - 29 May 2025
（This article belongs to the Special Issue: Recent Advances in Cancer Pharmacology)
Abstract Objectives: Triphenylphosphine (TPP) and Doxorubicin (DOX) were conjugated to obtain Triphenylphosphine-Doxorubicin (TPP-DOX), which was applied in tumor cells for enhancement of DOX in mitochondria targeting. The study focused on investigating the anti-tumor effect of TPP-DOX in combination with radiotherapy throughout in vitro and in vivo studies. Methods: TPP-DOX was synthesized using the carbodiimide method. In vitro experiments were conducted with 4T1 cells (mouse breast cancer cell line) to assess apoptosis induction, mitochondrial targeting, reactive oxygen species (ROS) production, and mitochondrial membrane potential. The research evaluates the effects of TPP-DOX, DOX, and their combinations with radiotherapy. A nude mouse… More >

Graphic Abstract

View

715

Download

367

Open Access

ARTICLE

CHUCHU ZHANG^1,#, YING LIU^2,#, ZEHUI CHEN¹, YI LIU³, QIYUAN MAO⁴, GE ZHANG⁵, HONGSHENG LIN⁴, JIABIN ZHENG^6,*, HAIYAN LI^1,*
Oncology Research, Vol.33, No.6, pp. 1437-1458, 2025, DOI:10.32604/or.2025.059290 - 29 May 2025
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis)
Abstract Objectives: Decades of clinical and fundamental research advancements in oncology have led to significant breakthroughs such as early screening, targeted therapies, and immunotherapy, contributing to reduced mortality rates in cancer patients. Despite these achievements, cancer continues to be a major public health challenge. This study employs bibliometric techniques to visually analyze the English literature on cancer prevention, screening, diagnosis, treatment, and rehabilitation. Methods: We systematically reviewed publications from 01 March 2014, to 01 March 2024, indexed in the Web of Science core collection. Tools such as VOSviewer Version 1.6.20 is characterized by its core idea… More >

Graphic Abstract

View

799

Download

419

Open Access

ARTICLE

DEXUE FAN^1,#, WEI SU^2,#, ZHAOWEN BI³, XINXING WANG¹, XIANWEN XU¹, MINGZE MA⁴, LICHAO ZHU⁵, ZHENHAI ZHANG^1,3,*, JUNLIN GAO^2,*
Oncology Research, Vol.33, No.6, pp. 1459-1472, 2025, DOI:10.32604/or.2025.060407 - 29 May 2025
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Objectives: Apatinib has been reported to be a promising treatment for sorafenib-resistant hepatocellular carcinoma (HCC) patients. However, the underlying mechanism remains ambiguous. The study aimed to explore the efficacy of apatinib in sorafenib-resistant HCC and the underlying mechanism both in vitro and in vivo. Methods: After observing epithelial-mesenchymal transformation (EMT) changes in HepG2 and HepG2/Sorafenib cells, we treated them with varying concentrations of apatinib to assess its impact on sorafenib-resistant HCC. Subsequently, specific inhibitors of c-Jun N-terminal kinase (JNK, SP600125) and extracellular signal-regulated kinase (ERK, PD98059) were introduced to investigate whether apatinib influenced sorafenib-resistant HCC via modulation… More >

View

647

Download

331

Open Access

ARTICLE

NURAN BEDOLLA^#, HAO WU^#, LINYU LIU, XUETING LIU, YANLI REN^*
Oncology Research, Vol.33, No.6, pp. 1473-1484, 2025, DOI:10.32604/or.2025.060151 - 29 May 2025
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Background: Gallic acid (GA), a plant-derived polyphenol, possesses diverse biological functions such as reducing inflammation and against tumors. Currently, the influence of GA on the resistance of esophageal squamous cell carcinoma (ESCC) cells to cisplatin (DDP) is not well understood. Methods: Cell counting kit-8 assay examined how GA affected KYSE30 and TE-1 cell viability. 5-Ethynyl-2′-deoxyuridine and TdT-mediated dUTP Nick-End labeling staining detected cell proliferation and apoptosis. Clone formation assay, flow cytometry, Carboxyfluorescein diacetate succinimidyl ester fluorescent probes, and Transwell assay determined cell biological properties, and 2′,7′-Dichlorofluorescin diacetate (DCFH-DA) fluorescent probes detected oxidative stress levels. Signal… More >

Graphic Abstract

View

644

Download

294

Open Access

ARTICLE

WENZHUO YANG^1,#, HAODONG CHEN^2,#, ZHILAN ZHANG³, ZHIYONG XIA³, YUANYUAN JIN^1,*, ZHAOYONG YANG^1,*
Oncology Research, Vol.33, No.6, pp. 1485-1494, 2025, DOI:10.32604/or.2025.059426 - 29 May 2025
Abstract Background: Human natural killer (NK) cells have attracted widespread attention as a potential adoptive cell therapy (ACT). However, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. There is an urgent need to explore a suitable new treatment plan to overcome weaknesses and support the superior therapeutic activity of NK cells. Methods: In this study, the mechanisms underlying the susceptibility of gastric cancer (GC) cell lines AGS, HGC-27, and NCI-N87 to NK cell-mediated cytotoxicity were explored. Results: Lactic dehydrogenase (LDH) release assays showed that all three GC cell lines were susceptible… More >

View

529

Download

260

Open Access

ARTICLE

LUCIANA SABOYA^1,2, KEINI BUOSI¹, TIAGO SILVA², ELAINE CANDIDO¹, JOSIANE MORARI³, LICIO A. VELLOSO³, SHAHROKH F. SHARIAT^4,5,6,7, MARCUS V. SADI², LEONARDO O. REIS^1,8,9,*
Oncology Research, Vol.33, No.6, pp. 1495-1503, 2025, DOI:10.32604/or.2025.061812 - 29 May 2025
（This article belongs to the Special Issue: Advances in Genitourinary Cancer)
Abstract Objective: To determine the safety and the role of modulating cytokines and proteases in the immune response to intravesical Bacillus Calmette-Guérin (BCG) when primed with systemic intradermal BCG. Methods: Phase 1 and mechanistic longitudinal, prospective, single-blind randomized study (NCT04806178). Twenty-one non-muscle invasive urothelial bladder cancer patients undergoing intravesical adjuvant BCG after transurethral resection of bladder tumor (TURBT) in a teaching hospital between September 2021 and April 2023 were randomized to 0.1 mL of intradermal BCG vaccine or placebo (0.9% saline) administered 15 days before the start of intravesical BCG therapy. Blood samples were evaluated mechanistically… More >

View

539

Download

433

Open Access

CORRECTION

YUANLIN LIU^1,3, YAN LIU², YAN WANG², QIANG WANG², YAN YAN¹, DANDAN ZHANG^2,*, HUIQIN LIU^2,*
Oncology Research, Vol.33, No.6, pp. 1505-1505, 2025, DOI:10.32604/or.2024.056768 - 29 May 2025
Abstract This article has no abstract. More >

View

179

Download

147

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.33, No.6, pp. 1507-1507, 2025, DOI:10.32604/or.2024.056917 - 29 May 2025
Abstract This article has no abstract. More >

View

222

Download

197

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.33, No.6, pp. 1509-1509, 2025, DOI:10.32604/or.2024.062048 - 29 May 2025
Abstract This article has no abstract. More >

View

198

Download

156